uploads/2018/11/human-skeleton-163715_1280.jpg

United Health Group Stock Has Risen 28% in 2018

By

Updated

Revenue trends

On November 29, United Health Group’s (UNH) stock price closed at $282.55, which is ~8% growth from its close of $261.62 on November 23. United Health Group’s stock price increased from $220.46 to $282.55 when the market closed on November 29, which reflects ~28% YTD (year-to-date) growth. On November 29, United Health Group hit its 52-week high of $285.45.

On November 29, United Health Group’s stock price closed at $282.55, which represents ~36% growth from its 52-week low of $208.48 on February 5.

Article continues below advertisement

Financials in a nutshell

United Health Group’s net revenues during the first nine months of 2018 were $167.8 billion—compared to $149.1 billion during the same period in 2017, which reflects ~12% YoY (year-over-year) growth. United Health Group’s revenue growth could boost the iShares U.S. Healthcare Providers ETF’s (IHF) share prices. United Health Group accounts for ~14.39% of IHF’s total portfolio holdings.

United Health Group’s premiums mainly contributed to the company’s revenue growth during the first nine months of 2018. The premiums generated revenues of $133.2 billion during the first nine months of 2018—compared to $118.1 billion during the same period in 2017, which reflects 13% YoY growth.

In the third quarter, United Health Group’s peers in the managed healthcare market, Cigna (CI) and Humana (HUM) reported revenues of $11.4 billion and $14.2 billion, respectively, which reflects 11.5% and ~6.39% YoY growth.

During the first nine months of 2018, United Health Group’s products and services generated revenues of $21.1 billion and $12.6 billion, respectively—compared to $19.2 billion and $11.1 billion during the same period in 2017.

United Therapeutics’ total operating cost during the first nine months of 2018 amounted to $155.0 billion—compared to $137.9 billion during the same period in 2017.

The company’ net income and diluted EPS during the first nine months of 2018 amounted to $8.9 billion and $9.09, respectively—compared to $6.9 billion and $7.49 during the same period in 2017.

Analysts’ recommendations

Among the 24 analysts tracking United Health Group (UNH) in November, ten recommended a “strong buy,” 13 recommended a “buy,” and one recommended a “hold.”

On November 30, United Health Group had a consensus 12-month target price of $309.41, which represents an ~9.51% return on investment over the next 12 months.

Advertisement

More From Market Realist